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Homocysteine (Hcy) is a non-protein aminoacid which is an intermediate of methionine metabolism. Elevated homocysteine 
level (hyperhomocysteinemia) is a risk factor of cardiovascular diseases. In addition, obesity and metabolic syndrome are 
associated with greater prevalence of atherosclerosis. The purpose of this article is to discuss the relationship between adipose 
tissue and Hcy metabolism. All enzymes involved in the synthesis and metabolism of Hcy are expressed in adipose tissue, and 
recent studies suggest that adipose tissue may be an important source of circulating homocysteine. The effect of obesity on Hcy 
level is controversial, however, most experimental and clinical studies indicate that Hcy is elevated in the metabolic syndrome 
in the absence of diabetes. Homocysteine elevation in the metabolic syndrome may result from either hyperinsulinemia or the 
impairment of renal function. In contrast, plasma Hcy is reduced in both type 1 and type 2 diabetes if renal function is normal, 
but becomes elevated when diabetic nephropathy develops. Leptin, which is markedly elevated in obese patients, has no effect 
on total plasma Hcy, but increases the level of homocysteine thiolactone – a cyclic thioester of homocysteine which plays an 
important role in complications of hyperhomocysteinemia. The effect of leptin is accounted for by the inhibition of paraoxonase 
1 (PON1) – the HDL-associated esterase, which hydrolyzes homocysteine thiolactone to Hcy. In addition, recent studies indicate 
that homocysteine may induce insulin resistance in adipose tissue by promoting endoplasmic reticulum stress and/or disrupting 
adipokine production; e.g. enhancing resistin and suppressing adiponectin. Biomed Rev 2009; 20: 7-15.
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INTRODUCTION
Homocysteine (Hcy) is a non-protein sulfur-containing ami-
noacid (Fig. 1). Homocysteine is derived from the metabo-
lism of methionine – the essential aminoacid which must be 
provided in the diet (Fig. 2). First, adenosine is transferred 
by methionine adenosyltransferase (MAT, SAM synthetase) 
from ATP to methionine to form S-adenosylmethionine 
(SAM). SAM is the universal donor of methyl groups for 
methylation reactions catalyzed by various methyltransferas-
es. When –CH3 group is transferred by methyltransferases to 
the respective acceptor, SAM is converted to S-adenosylho-
mocysteine (SAH) that is subsequently hydrolyzed by SAH 
hydrolase to adenosine and homocysteine (1). Homocysteine 
is metabolized in two pathways referred to as remethylation 
and transsulfuration. Remethylation of Hcy to methionine is 
mainly catalyzed by methionine synthase which uses 5-meth-
8
Biomed Rev 20, 2009
Bełtowski and Tokarzewska
Figure 1. Structure of sulfur-containing aminoacids.
Figure 2. Pathways of homocysteine synthesis and metabolism. SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; 
Pi, inorganic phosphate; PPi, inorganic pyrophosphate; THF, tetrahydrofolate; 5-CH3-THF, 5-methyltetrahydrofolate; MAT, 
methionine adenosyltransferase; MT, methyltransferases; SAHH, SAH hydrolase; CBS, cystathionine β-synthase; CSE, cystath-
ionine γ-lyase; MS, methionine synthase; BHMT, betaine:homocysteine methyltransferase.
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yltetrahydrofolate and vitamin B12 as cofactors. Alternative-
ly, some Hcy may be remethylated by betaine:homocysteine 
methyltransferase (BHMT) which uses betaine as a methyl 
donor. In the transsulfuration pathway, Hcy condenses with 
serine to form cystathionine in the reaction catalyzed by cys-
tathionine β-synthase (CBS). Cystathionine is then converted 
to cysteine and 2-oxobutyrate by cystathionine γ-lyase (CSE) 
(2). Recently, it has been demonstrated that homocysteine 
may also be the substrate for CSE (3). Indeed, CSE may 
condense two molecules of homocysteine to form homolan-
thionine (Hcy-S-Hcy) and hydrogen sulfide (H2S) – a novel 
physiologically relevant gasotransmitter (4). Both CBS and 
CSE use pyridoxal 5-phosphate (an active form of vitamin 
B6) as a cofactor.
Homocysteine circulates in the blood at a concentration 
of ~10 μM. In plasma, about 2/3 of total Hcy is bound to 
protein cysteine residues by disulfide bridges (Hcy-protein 
disulfides) and most of the remaining 1/3 circulates in oxi-
dized form as low-molecular weight disulfides, homocystine 
(Hcy-S-S-Hcy) or Hcy-S-S-cysteine. Only about 1% of total 
Hcy circulates in free reduced form (1, 2).
It was noted in 1960s that the risk of atherosclerosis is 
markedly increased in patients with homocystinuria – the in-
herited disease resulting from homozygous CBS deficiency 
which is characterized by episodes of thromboembolism, 
mental retardation, lens dislocation, hepatic steatosis and 
osteoporosis. In these patients, plasma Hcy usually exceeds 
100 μM. Much more frequent (5-10% of the general popu-
lation) is mild to moderate hyperhomocysteinemia (plasma 
Hcy 15-40 μM), which also increases the risk of atheroscle-
rosis. The most common causes of hyperhomocysteinemia 
include heterozygous CBS deficiency, thermolabile variant 
of methylenetetrahydrofolate reductase (MTHFR) resulting 
from C677T polymorphism of MTHFR gene, deficiency of 
vitamins involved in Hcy metabolism (folate, B6 and B12), 
renal impairment and high methionine intake (5). Apart 
from atherosclerosis, hyperhomocysteinemia is also associ-
ated with several other health burdens including Alzheimer’s 
disease and other forms of dementia, osteoporosis, cancer, 
as well as complications of pregnancy such as intrauterine 
growth restriction, preeclampsia, miscarriages and neural 
tube defects in the neonate.
Metabolic syndrome (MS) is a cluster of pathologies 
which directly or indirectly result from obesity. Several com-
ponents of the metabolic syndrome such as insulin resistance 
and compensatory hyperinsulinemia, hypertriglyceridemia, 
low HDL-cholesterol, arterial hypertension, proinflamma-
tory and prothrombotic state, impaired glucose tolerance or 
type 2 diabetes are independent risk factors of atherosclero-
sis. In addition, MS is associated with the dysregulation of 
adipose tissue-derived signaling proteins collectively termed 
adipokines (6). Some of adipokines such as leptin, resistin 
and visfatin promote atherosclerosis, whereas adiponectin, 
interleukin-10, nerve growth factor and brain-derived neuro-
trophic factor are atheroprotective mediators (6). Due to high 
prevalence of both obesity/MS and hyperhomocysteinemia, 
the relationship between adipose tissue and homocysteine 
metabolism is of great significance. 
The purpose of this review is to summarize the current 
knowledge about role of adipose tissue in homocysteine me-
tabolism, the effect of obesity/MS on homocysteine, and the 
effect of hyperhomocysteinemia on adipose tissue.
ADIPOSE TISSUE AS A SITE OF HOMOCYSTEINE SYNTHESIS 
AND METABOLISM
Methylation reactions are essential for the metabolism of 
lipids, proteins and nucleic acids, and methionine-to-homo-
cysteine pathway (Fig. 2) is operative in all tissues including 
the adipose tissue. Recent studies (7, 8) indicate that histone 
methylation is essential for the expression of two transcrip-
tion factors crucial for adipogenesis, peroxisome prolifera-
tor-activated receptor-γ (PPAR-γ) and CCAT enhancer bind-
ing protein-α (C/EBP-α). Adipose tissue also contains pro-
tein methyltransferases involved in formation of asymmetric 
dimethylarginine (ADMA) – an endogenous nitric oxide 
synthase inhibitor – from its precursor, L-arginine (9), and 
phospholipid methyltransferases (10). Recently, Riederer et 
al. (11) have demonstrated that nicotinamide N-methyltrans-
ferase (NNMT), which methylates nicotinamide and nico-
tinic acid (vitamin B3) is expressed in adipocytes. Interest-
ingly, the expression of NNMT was higher in white adipose 
tissue than in the liver which was previously considered as 
the main NNMT-containing organ. NNMT is also expressed, 
although at lower level, in brown adipose tissue. NNMT 
expression and activity markedly increased during the dif-
ferentiation of preadipocytes to mature fat cells. In addition, 
homocysteine was produced and secreted to the medium by 
3T3-L1 preadipocytes and its release increased six-fold dur-
ing their differentiation to adipocytes (11). Chronic treatment 
with nicotinic acid increased NNMT expression and activity 
in murine adipose tissue but not in the liver. Obesity induced 
by high-fat diet also increased NNMT in murine adipose tis-
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sue. Moreover, nicotinamide increased, whereas NNMT in-
hibitor decreased homocysteine production in adipose tissue 
by about 50%, indicating that NNMT is an important source 
of homocysteine in adipocytes (11). These data indicate that 
adipose tissue may be an important source of circulating ho-
mocysteine.
It is unclear if remethylation pathway is operative in adi-
pocytes. However, both CBS and CSE are expressed and ac-
tive in perirenal, epidydimal and perivascular white adipose 
tissue, as well as in brown adipose tissue (12, 13).
EFFECT OF OBESITY/METABOLIC SYNDROME ON PLASMA 
HOMOCYSTEINE LEVEL
The impact of obesity/metabolic syndrome on homocysteine 
metabolism is controversial and most likely reflects the com-
plex, sometimes oppose, effects of various MS components. 
Fonseca et al (14) demonstrated that experimental obesity 
induced by high fat and high sucrose feeding resulted in al-
most 50% elevation of plasma homocysteine in the rat. In 
this model, plasma glucose was normal but hyperinsulinemia 
and insulin resistance were observed. Hepatic CBS expres-
sion and activity were reduced and negatively correlated 
with both plasma insulin and homocysteine. In contrast, he-
patic MTHFR activity was higher in obese animals, indicat-
ing that remethylation pathways is intact or even improved 
and that reduced transsulfuration is responsible for hyperho-
mocysteinemia. Similarly, metabolic syndrome induced by 
high-fructose feeding, which is associated with severe insulin 
resistance, hyperinsulinemia, hypertriglyceridemia and arte-
rial hypertension but not hyperglycemia or obesity, resulted 
in 70% elevation of plasma homocysteine in the rat (15). 
In addition, homocysteine level positively correlated with 
plasma insulin and triglycerides. Hyperhomocysteinemia 
in these animal models may be associated with high insulin 
level. Indeed, insulin reduces CBS activity in the liver (16, 
17). Streptozotocin-induced diabetes – the state of insulin de-
ficiency – is characterized by high CBS and CSE activities 
in the liver and low plasma homocysteine level, and insulin 
supplementation corrects these abnormalities (18).
In contrast to these studies, plasma homocysteine was 
normal in Zucker fatty rats – an experimental model of obes-
ity and insulin resistance associated with the mutation of the 
leptin receptor (19). However, a peroxisome proliferator acti-
vated receptor gamma (PPAR-γ) agonist, troglitazone, which 
increases insulin sensitivity and reduces fasting insulin level, 
decreased plasma Hcy and increased CBS activity in the liver 
of obese rats (19). Wijekoon et al. (20) found that plasma 
Hcy was 25% lower in Zucker diabetic fatty (ZDF) rats at 
5th week of age when these animals are insulin resistant and 
hyperinsulinemic but still nonrmoglycemic. In that study, in-
crease in the activities of several enzymes involved in Hcy 
metabolism including CBS, CSE, MTHFR and BHMT in 
the liver was observed (20). In contrast, methionine synthase 
activity was slightly but significantly reduced in these ani-
mals. However, in parallel with increased metabolism, Hcy 
formation might also be enhanced since MAT activity was 
greater in ZDF than in control lean rats (20). Furthermore, 
insulin sensitizer, rosiglitazone, has been show to reduce Hcy 
level in animal models of insulin resistance or hyperhomo-
cysteinemia (21, 22).
Data about the relationship between metabolic syndrome 
and homocysteine in humans are also controversial. Homo-
cysteine was positively correlated with body mass index 
(BMI), absolute fat mass, percentage of fat mass, and fast-
ing insulin level in obese children and adolescents (23). In 
the Framingham Offspring Study including 2011 nondiabet-
ic subjects, plasma homocysteine was higher in those with 
hyper- than in those with normoinsulinemia (24). Sanchez-
Margalet et al. (25) observed that plasma Hcy was higher in 
hyperinsulinemic than in normoinsulinemic obese non-dia-
betic males, although folate and vitamin B12 levels were not 
different between groups. In addition, fasting homocysteine 
significantly correlated with fasting insulin in these patients 
(25). An independent association between insulin resistance 
and plasma Hcy was also observed in healthy non-obese 
subjects (26). De Pergola et al. (27) compared Hcy levels 
in apparently healthy normal weight, overweight and obese 
premenopausal women, and found gradual increase in Hcy 
from normal weight to obese group. However, in multivariate 
analysis only insulin resistance but not BMI, age or waist cir-
cumference was independently associated with Hcy level. In 
addition, plasma Hcy was higher in 80 obese than in 50 non-
obese subjects, however, there was no correlation between 
Hcy and plasma insulin, BMI or waist-to-hip ratio (WHR) in 
either non-obese or obese group (28). Recently, Bukhari et 
al. (29) reporter that Hcy was much higher in 160 obese than 
in 160 lean patients in the Pakistani population. Positive as-
sociation between Hcy and insulin levels was also observed 
in insulin-resistant women with polycystic ovarian syndrome 
(30) and preeclampsia (31).
In contrast, Abbasi et al. (32) observed no relationship be-
tween insulin-induced glucose disposal and Hcy in healthy 
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volunteers. Similarly, Gómez-Ambrosi et al. (33) observed 
no difference in Hcy levels between lean and obese males. 
Godsland et al. found no relationship between plasma Hcy 
and insulin sensitivity in healthy men (34), whereas Rosolo-
vá et al. (35) found the inverse correlation between homo-
cysteine and insulin resistance. Bar-On et al. (36) demon-
strated a significant negative correlation between plasma Hcy 
and insulin in an epidemiological cross-sectional study.
These discrepancies may be accounted for by several fac-
tors. First, taking into account that insulin reduces hepatic 
CBS activity (16), the extent of hyperinsulinemia and insulin 
resistance is significant. If insulin resistance is confined to 
its effect on glucose disposal in peripheral tissues whereas 
hepatic effect of insulin is intact, hyperinsulinemia will im-
pair Hcy metabolism in the liver. However, if the liver is 
insulin resistant, the inhibitory effect of insulin on hepatic 
CBS would be impaired, and Hcy metabolism might even 
be accelerated. Second, insulin has the anabolic effect on 
protein metabolism and may reduce intracellular methionine 
available for Hcy production. Third, alimentary intake of 
methionine, folate, vitamin B6 and B12 may determine the 
effect of hyperphagia and obesity on Hcy level. Fourth, the 
kidney is one of the major organs involved in homocysteine 
metabolism (37). Obesity and metabolic syndrome are often 
associated with glomerular hyperfiltration, which may en-
hance renal Hcy clearance (38). On the other hand, obesity 
and metabolic syndrome may impair renal function even in 
the absence of other risk factors such as diabetes or hyper-
tension (39). Impaired renal function is always accompanied 
by hyperhomocysteinemia (40). Fifth, Hcy level depends on 
whether diabetes is present or not in patient with the meta-
bolic syndrome. While metabolic syndrome with normogly-
cemia may be associated with hyperhomocysteinemia, ex-
perimental and clinical studies consistently show that plasma 
Hcy is reduced in both type 1 and type 2 diabetes mellitus if 
there is no nephropathy (18, 41), and increases in diabetic 
patients only when nephropathy develops (42, 43). Finally, it 
cannot be excluded that insulin resistance is the consequence 
rather than the cause of hyperhomocysteinemia (see below).
LEPTIN, HOMOCYSTEINE THIOLACTONE AND 
PARAOXONASE 1
Multiple studies performed during the last decade indicate 
that adipokines play an important role in the pathogenesis of 
metabolic syndrome and its complications. We examined the 
effect of experimental hyperleptinemia induced in lean rats 
by the administration of exogenous leptin at doses, which el-
evate its level to the range observed in obesity. This model al-
lows studying the effects of leptin excess isolated from other 
abnormalities observed in obesity. We found that leptin had 
no effect on total plasma homocysteine in the rat. However, 
leptin increased the amount of homocysteine thiolactone 
bound to plasma proteins (44). Homocysteine thiolactone is 
a cyclic thioester of homocysteine formed when Hcy is non-
specifically bound by methionyl-tRNA synthetase. Although 
Hcy may bind methionyl-tRNA synthetase, it is not incor-
porated into proteins but is converted to Hcy-thiolactone. 
Thiolactone is probably one of the most detrimental forms 
of Hcy. Indeed, Hcy-thiolactone binds to ε-NH2 groups of 
protein lysine residues even at very low concentrations, 
whereas many other toxic effects of Hcy are observed only 
at high concentrations, markedly exceeding its physiologic 
and even pathologic levels. Homocysteinylated proteins have 
altered properties and impaired biological activity, and may 
also induce the immune response. Augmentation of protein 
homocysteinylation was observed in patients with hyperho-
mocysteinemia, renal impairment or coronary heart disease 
(45). Importantly, protein-bound Hcy-thiolactone is omitted 
by most routine methods of plasma Hcy assay, because its 
measurement requires prior hydrolysis of plasma proteins. 
Hcy-thiolactone is hydrolyzed to open-form Hcy by two 
enzymes: extracellular paraoxonase 1 (PON1), synthesized 
in the liver and circulating in high-density lipoproteins, and 
intracellular cysteinyl protease, bleomycin hydrolase (BLH). 
We found that experimental hyperleptinemia decreased plas-
ma PON1 activity, which resulted in almost two-fold eleva-
tion of protein-bound Hcy-thiolactone despite normal total 
Hcy level (44). PON1 deficiency was observed in obesity/
metabolic syndrome (46) and, in some studies, negative cor-
relation between PON1 and leptin was observed in obese 
subjects (47). In addition, multiple experimental and clinical 
studies indicate that hyperleptinemia promotes atherogenesis 
(48). Taken together, these data indicate that leptin-induced 
PON1 deficiency impairs metabolism of Hcy-thiolactone, 
leading to the enhancement of protein homocysteinylation. 
This mechanism may contribute to atherogenesis in obese 
subjects.
EFFECT OF HYPERHOMOCYSTEINEMIA ON ADIPOSE 
TISSUE
Not only the amount of adipose tissue in patients with the 
metabolic syndrome may affect Hcy metabolism but also 
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vice versa, hyperhomocysteinemia affects adipose tissue 
function. Indeed, it has been demonstrated that Hcy and Hcy-
thiolactone impair insulin signaling by inducing oxidative 
stress and reducing insulin receptor tyrosine kinase activity 
(49,50). Golbahar et al (51) have shown that experimental hy-
perhomocysteinemia induced in Sprague-Dawley rats by the 
administration of homocysteine in the drinking water for 50 
days induced insulin resistance, as evidenced by higher fast-
ing insulin level and HOMA index, whereas plasma glucose 
and body weight were not altered. Authors suggested that 
Hcy-induced insulin resistance could have been associated 
with impaired endothelial function. Hyperhomocysteinemia 
induces endothelial dysfunction, and impaired endothelium-
dependent relaxation of the skeletal muscle microvasculature 
is well known to contribute to insulin resistance by impair-
ing glucose disposal. In support of this hypothesis, lowering 
plasma Hcy with folate and vitamin B12 improved insulin 
sensitivity in humans (52).
Recently, Li et al (53) have demonstrated that hyperhomo-
cysteinemia induced by a 4-week oral administration of ho-
mocysteine induced insulin resistance in mice. Interestingly, 
in that study plasma Hcy was increased less than three-fold 
but Hcy in adipose tissue was about seven-fold higher than 
in control normohomocysteinemic animals. Body weight, 
plasma triglycerides and HDL cholesterol were similar in 
normo- and hyperhomocysteinemic mice, but total cholester-
ol was increased in hyperhomocysteinemic animals. Moreo-
ver, hyperhomocysteinemia reduced tyrosine phosphoryla-
tion of the insulin receptor and insulin receptor substrate-1 
(IRS-1), but increased serine phosphorylation of IRS-1 in 
adipose tissue. Phosphorylation of IRS-1 by various serine/
threonine protein kinases impairs its phosphorylation by the 
insulin receptor tyrosine kinase. and is a common mechanism 
of insulin resistance. Phosphorylation of protein kinase B/
Akt, a downstream kinase of IRS-1, was also impaired in 
adipose tissue of hyperhomocysteinemic animals (53). These 
data indicate that homocysteine disrupts insulin signaling in 
adipose tissue. Furthermore, Hcy inhibited insulin receptor-
IRS-1-Akt signaling pathway, increased serine phosphoryla-
tion of IRS-1, and reduced 2-deoxyglucose uptake by cul-
tured rat adipocytes in vitro (53). Interestingly, hyperhomo-
cysteinemia increased resistin production both in vivo and 
in vitro. Resistin expression in epidydimal adipose tissue 
at both mRNA and protein level was increased in hyperho-
mocysteinemic mice as was plasma resistin concentration. 
Hyperhomocysteinemia was also associated with the up-
regulation of tumor necrosis factor-α (TNF-α) and plasmino-
gen activator inhibitor-1 (PAI-1) in adipose tissue, whereas 
leptin expression was reduced in homocysteine-treated mice. 
Furthermore, it was demonstrated that Hcy induced resistin 
expression in adipocytes by increasing intracellular forma-
tion of reactive oxygen species (ROS), stimulating protein 
kinase C (PKC), and increasing DNA-binding activity of 
nuclear factor-κB (NF-κB) (53). These data suggest that re-
sistin may be involved in Hcy-induced insulin resistance, al-
though oxidative stress, PKC and NF-κB may also directly 
impair insulin signaling. Song et al. (54) have demonstrated 
that Hcy decreased adiponectin synthesis in isolated rat adi-
pocytes, and that high methionine diet-induced hyperhomo-
cysteinemia suppressed adipose tissue adiponectin produc-
tion and reduced plasma adiponectin concentration in the 
rat. In addition, homocysteine-induced hypoadiponectinemia 
resulted in the reduction of AMP-stimulated protein kinase 
(AMPK) which mediates beneficial effects of adiponectin 
on carbohydrate and lipid metabolism in the liver. Effect of 
Hcy on adiponectin production was mediated by the inhibi-
tion of extracellular signal-regulated kinases (ERKs), since 
homocysteine reduced ERK activity in adipocytes, and ERK 
inhibitors, U0126 and PD98059, mimicked the inhibitory ef-
fect of Hcy (54). In addition, it has been demonstrated that 
homocysteine induced endoplasmic reticulum (ER) stress 
in adipocytes, as evidenced by the induction of ER stress 
marker, C/EBP homologous protein (CHOP). The ER stress 
inducer, thapsigargin, also reduced adiponectin production. 
ER stress not only suppresses adiponectin, but also stimu-
lates resistin production (55), induces adipose tissue inflam-
mation (56), and impairs insulin signaling in adipocytes (57). 
Adipocyte ER stress is observed in obesity (57) and is re-
duced by weight loss (58). Thus, ER stress may be a common 
mechanism of adipocyte dysfunction in both obesity and hy-
perhomocysteinemia. Last not least, Hcy and folic acid are 
also implicated in the regulation of coronary circulation as 
well as the pathogenesis of coronary artery disease (59).
CONCLUSIONS
Obesity/metabolic syndrome and hyperhomocysteinemia are 
two common risk factors of cardiovascular disorders. Recent 
studies indicate that bidirectional relationships between adi-
pose tissue and homocysteine metabolism exist. Adipose tis-
sue may be the source but also the site of metabolism of ho-
mocysteine. Plasma homocysteine is increased in obese insu-
lin resistant patients who are not diabetic. Adipokines have 
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an important impact on homocysteine metabolism. For ex-
ample, leptin has no effect on total plasma homocysteine but, 
by reducing PON1 activity, impairs the metabolism of ho-
mocysteine thiolactone and enhances homocysteinylation of 
plasma proteins. On the other hand, hyperhomocysteinemia 
has pleiotropic effects on adipose tissue, i.e. induces insulin 
resistance, ER stress, and dysregulates adipokine secretion.
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